Original Research Article

Assessment of role of genetic polymorphisms in XRCC1, XRCC2 and XRCC3 genes in cervical cancer susceptibility from a rural population: a hospital based case-control study from Maharashtra, India

Kailas D. Datkhile1*, Madhavi N. Patil1, Pratik P. Durgawale1, Shreepad A. Joshi1, Kalpita S. Korabu1, Satish V. Kakade2

1Department of Molecular Biology and Genetics, 2Department of Preventive and Social Medicine, Krishna Institute of Medical Sciences University, Karad, Satara, Maharashtra-415110, India

Received: 10 July 2018
Accepted: 06 August 2018

*Correspondence:
Dr. Kailas D. Datkhile,
E-mail: hodgeneticslab@kimsuniversity.in

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Cervical cancer is a major concern of health risk, moreover the leading cause of cancer causing deaths in women of rural parts of India. This study was aimed to assess the risk of cervical cancer development in association with polymorphisms in X-Ray Cross Complementing Group (XRCC1, XRCC2 and XRCC3) genes in the rural population of south-western Maharashtra. We focused to determine the frequency of polymorphisms in DNA repair genes including XRCC1 at codon (cd) 194, cd 280, cd 399, XRCC2 at cd 188 and XRCC3 at cd 241 and their plausible role in cervical cancer risk from rural parts of India.

Methods: This study included 350 proven cases with cervical cancer and 400 age and sex matched controls. We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to analyze the association XRCC1, XRCC2 and XRCC3 gene polymorphisms with cervical cancer development in women of South-Western Maharashtra.

Results: The result from our study showed that allele frequencies of selected genes were not statistically different between the groups for XRCC1 Trp194, XRCC2 His188 and XRCC3 Met241. XRCC1 His280 (OR= 4.36; 95% CI= (3.20-5.95); p= <0.0001) and XRCC1 Gln399 (OR= 2.99; 95% CI= (1.60-5.56); p= <0.0001) genotypes significantly increased the risk of cervical cancer.

Conclusions: This study indicates that polymorphisms in cd 280 of exon 9 and cd 399 of exon 10 of XRCC1 gene could play a role in modifying genetic susceptibility of individuals towards cervical cancer among women from rural Maharashtra. This case-control study suggest that selected DNA repair genes represent genetic determinants in cervical carcinogenesis along with other risk factors in the rural Indian population.

Keywords: Cervical cancer, Genetic polymorphisms, PCR-RFLP, XRCC1, XRCC2, XRCC3

INTRODUCTION

Cervical cancer (CC) is one of the most common genital tract carcinomas which has become an exigent health concern and the fourth leading cause of cancer related death among women world over.1,2 In developing countries, the highest incidence rates of CC are observed in Africa, Caribbean, South, Central and Southeast Asia. India has the highest burden of CC where approximately 1,34,420 women are diagnosed with the disease every year, and of them 72,825 deaths accounting for nearly one-fifth of the global CC burden alone.3 The number of CC deaths in women from India by the year 2010 was 79,000 and it is estimated that by the year 2025 there will be almost 20 million new cases. Over the last 20 years, it is universally implicated that along with tobacco and alcohol, persistent infection with high risk Human
Papilomavirus (HPV) and other sexually transmitted agents are necessary etiologic factors for cervical carcinogenesis. In India many findings from rural areas have showed higher incidence of HPV infection in different age groups where the prevalence rate could be probably due to preventive measures for management of CC. Although tobacco, alcohol and HPV are the main etiologic factors for three fourth of these cancer cases, no definite etiologic factor can be identified in one fourth of the cases. In those cases development of cervical cancer could be influenced by genetic factors. Identification of such genetic variants associated with CC may contribute to understand mechanisms underlying behind development of cancer.

The exogenous risk factors including environmental chemical agents and carcinogens in tobacco, such as nicotine and nitrosamines can induce DNA damage. DNA repair system is known to play a decisive role in protection of DNA against damage and essential for maintaining the genomic integrity. Until now, in human cells, more than a hundred molecules implicated in different DNA repair pathways such as base excision repair (BER), nucleotide excision repair (NER), double strand break repair (DSBR) and DNA mismatch repair (DMR). The X-Ray cross-complementing (XRCC) genes were initially discovered as an important component of DNA repair pathway contributing to genetic stability which have been extensively studied in the association with various human cancers. The DNA repair enzyme XRCC1 gene is a major component of BER pathway which plays an important role in repair of single strand breaks XRCC2 and XRCC3 are DSB repair genes, key mediators in homologous recombination repair (HRR) of DNA double strand breaks.

Genetic polymorphisms within the genes involved in DNA damage response may contribute to augmented risk of cancer development. In past few years, there has been extensive concern in identifying genetic variability in DNA repair genes and their impact on altering an individual’s susceptibility to cancer but the former observations were not consistent in terms of their role in cancer susceptibility. Some recent studies proposed the association of the polymorphisms in XRCC1 gene with multiple cancer risk such as lung, gastric, breast prostate and head and neck cancer. The polymorphism in XRCC2 gene is studied for its role in carcinogenesis of breast cancer. Likewise, XRCC3 gene polymorphism has been associated with the increased risk of lung and breast cancer. However, the results of former studies remain controversial rather than convincing in terms of the association between genetic polymorphisms of XRCC genes and risk of different cancer types and the influence of the polymorphisms of XRCC genes on DNA repair capacity still remains unanswered episode.

Also, significance of those DNA repair genes for cervical cancer is being investigated in recent years. Number of studies were conducted to investigate the association between XRCC1 (Arg194Trp, Arg280His, Arg399Gln) and XRCC3 Thr241Met polymorphisms and risk of cervical cancer in women. Some reports stated that XRCC2 (Arg188His) polymorphisms may be involved in repair of HPV related DNA damage in cervical cancer. But the results were debatable where few observations were not consistent in terms to show association between polymorphisms of XRCC1 Arg194Trp and development of cervical cancer, while the influence of the Arg280His polymorphisms acted as protective factor for squamous cervical carcinoma and Arg399Gln polymorphism increased cervical carcinogenesis among women whose age at first delivery was 20 years.

Also, few studies form India have been carried out to investigate association of XRCC1 gene with CC risk especially from Northern India and Southern India but they did not lead to a broad strapping conclusions. Consequently, the association between genetic polymorphism of XRCC1, XRCC2, XRCC3 and susceptibility to CC is still an open platform for illustration. Therefore, in this study we focused to evaluate role of genetic polymorphisms of XRCC1 at cd 194, cd 280, cd 399, XRCC 2 at cd 188 and XRCC3 at cd 241 in the development of CC if any. We performed a hospital-based case-control study with a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay to determine genotypic frequency of the selected i) XRCC1 gene at exon 6, exon 9 and exon 10 (ii) XRCC2 gene at exon 3 (iii) XRCC3 gene at exon 7 and their associations in the CC risk from rural population of Western Maharashtra from India.

**METHODS**

This study was a hospital-based case-control study. Study participants included 350 newly diagnosed CC patients and 400 healthy, cancer free, age and sex matched individuals as controls. All cases ranged in age from 20-80 years (Mean±SD) 48.67±13.78 were recruited immediately after being diagnosed during the year 2014-2017. Trained interviewers used a structured questionnaire to collect personal interview data from the participants regarding demographic factors and known risk factors. The study was approved by the Institutional Ethics Committee of the Krishna Institute of Medical Sciences ‘Deemed to be University’. Five milliliter (mL) of whole blood from patients and normal controls was collected in sterile vacutainer after receiving written informed consent. Genomic DNA extraction was carried out from the peripheral blood sample using Purelink genomic DNA extraction and purification kit (Invitrogen, Life technologies) following the manufacturer’s instructions.

Genotyping of XRCC1, XRCC2 and XRCC3 genes was performed by PCR-RFLP methods with appropriate primer sets. The primers were designed to amplify the regions of DNA that contain polymorphic sites of
interest; XRCC1 Arg194Trp in the exon 6 (C26304T), XRCC1 Arg280His in the exon 9 (G27466A), XRCC1 Arg399Gln in the exon 10 (G28152A), XRCC2 Arg188His in the exon 3 (G31479A), XRCC3 Thr241Met in the exon 7 (C18067T). PCR amplification were carried out separately under specific conditions in 20 micro liter (μL) reaction mixtures containing 100 nanogram (ng) of purified genomic DNA template, 1X PCR buffer (10 mili molar (mM) Tris-HCl (pH 9.0), 50 mM KCl 1.5 mM MgCl2), 0.2 mM each dNTP, 1U Taq DNA polymerase (GenNei, Merck Bioscience) and 10 picomole (pmol) of each primers. The primers selected to amplify the exons of XRCC1 containing the polymorphisms of interest were: XRCC1 (exon 6) sense primer: 5'-GCCAGGGCCCTCCTTTCAA-3' antisense primer: 5'-TACCTCAGACCCCAAGAT-3'; XRCC1 (exon 9) sense primer: 5'-CCAGCTCCAACTCTGACC-3' antisense primer: 5'-ATGAAGTGGTGTCGGTGTC-3'; XRCC1 (exon 10) sense primer: 5'-CAGTGGTGCTAACCTAATC-3' antisense primer: 5'-AGTATG CTCGTCGTCTTG-3'; XRCC2 (exon 3) sense primer: 5'-GTTGCGTCCATGGCTTACA-3' antisense primer: 5'-TGTAATCACCCATCTCTCCTGC-3' and XRCC3 (exon 7) sense primer: 5'-GGTCAGTACGTTCCA AAC-3' antisense primer: 5'-TGCAACGGCTGAGGGTCTT-3'. The PCR conditions for amplification of XRCC1 codon 194 in the exon 6 of 485 bp and XRCC1 codon 280 in the exon 9 of 257 bp were initial denaturation at 95°C for 10 minutes (min) followed by 30 cycles of 95°C- 30 seconds (sec), 61°C- 30 sec, 72°C- 30 sec and final extension at 72°C for 10 min. The conditions for XRCC1 codon 399 in the exon 10 of 871 bp were initial denaturation at 95°C for 10 min followed by 30 cycles of 95°C-20 sec, 56°C- 30 sec, 72°C-20 sec and final extension at 72°C-10 min. The PCR conditions for XRCC2 codon 188 in the exon 3 of 290 bp initial denaturation at 95°C for 10 min, followed by 30 cycles of 95°C-30 sec, 58°C-30 sec, 72°C-30 sec and 72°C-10 min and XRCC3 codon 241 in the exon 7 of 455 bp (95°C-10 min, 30 cycles of 95°C- 30 sec, 53°C-30 sec, 72°C-30 sec, 72°C-10 min). After performing PCR programme for each of the reactions with a Master Cycler Gradient PCR (Eppendorf), the PCR products were analyzed by agarose gel electrophoresis in Tris-Acetate-EDTA (TAE) buffer after staining with ethidium bromide (10mg/mL) and visualized under UV-transilluminator and photographed in gel documentation system (BioRad Laboratories).

After confirmation of DNA amplification, each PCR product of XRCC1 exon 6, exon 9 and exon 10 were digested overnight at 37°C with 1 unit (U) of restriction enzymes PvuII, Rsal and NciI respectively. Similarly, PCR product of XRCC2 exon 3 and XRCC3 exon 7 were digested overnight at 37°C with 1U of restriction enzyme HphI and 1U NlaII respectively. After the overnight incubation at 37°C, restriction digestion products were separated on a 2-3% low EEO agarose (GenNei, Merck Biosciences) gel at 100 V for 30 min, stained with ethidium bromide and photographed with gel documentation system.

Statistical analysis

The associations between the XRCC1, XRCC2 and XRCC3 genotypes and risk of CC development were studied using odds ratio (OR). Both the univariate and multivariate logistic regression analyses were employed to calculate the adjusted ORs and 95% confidence intervals (CIs) to determine the CC risk associated with genotypes. For each polymorphism the χ2 test was used to evaluate differences in the frequency distribution of selected demographic variables and the frequencies of allele and genotype of the polymorphisms between CC cases and the controls.

RESULTS

Characteristics of the study subjects

During the study period 350 patients with CC met the eligibility criteria for this study and 400 controls were selected to match these cases. The characteristics of age and sex matched cases and controls are presented in Table 1.

The mean age in years was 48.67 (median: 47, range 20-80) for the cases and 42.37 (median: 40 range 20-80) for the controls. There were no significant differences between the cases and controls with respect to sex and ethnicity. Stratification of other risk factors was performed by considering factors such as age, tobacco chewing status, diet and age at first pregnancy. Among women having their first intercourse and child birth after the age of 20, there was a significant association for cervical carcinogenesis determined using multivariate logistic regression analysis (Table 3).

Analysis of the Arg194Trp, Arg280His and Arg399Gln polymorphism in the XRCC1 gene

The distribution of XRCC genotypes and concordance of the three polymorphisms are presented in Table 2. The frequency of XRCC1 26304CC homozygotes was 79.71% in cases and 79.00% in controls whereas XRCC1 26304 TT homozygotes was 0.00% in cases and 1.50% in controls. The frequency of XRCC1 26304 CT heterozygotes was 20.29% in cases and 21.00% in controls. In codon 280, genotype frequencies for wild and variant genotypes were 39.14 and 60.86 per cent respectively in cases and 73.75 and 26.25 percent respectively in controls which showed significant difference in cases than controls. The frequency of XRCC1 28152GG homozygous wild type alleles at codon 399 of exon 10 was 39.14%, 28152GA heterozygote alleles was 52.29% and for 28152AA homozygous alleles was 8.57% in the cases where that of the frequencies for the controls were 61.50, 34.00 and 4.50 % respectively (Table 3).
Table 1: Distribution comparisons of selected demographic characteristics of cervical cancer cases and healthy controls from rural areas of Maharashtra in India.

| Variable                        | Cases N=350   | Controls N=400 | P-Value based on $\chi^2$ |
|---------------------------------|---------------|----------------|---------------------------|
| Age (Mean ± SD) years           |               |                |                           |
| ≤ 50                            | 216 (61.71%)  | 286 (71.50%)   | 0.003                     |
| 51-60                           | 58 (16.58%)   | 68 (17.00%)    |                           |
| 61-70                           | 56 (16.00%)   | 33 (08.25%)    |                           |
| >70                             | 20 (5.71%)    | 13 (03.25%)    |                           |
| Tobacco smoking Status          |               |                |                           |
| Tobacco users                   | 189 (54.00%)  | 112 (28.00%)   | <0.001                    |
| Tobacco no users                | 161 (46.00%)  | 288 (72.00%)   |                           |
| Age @ 1st Pregnancy (yrs)       |               |                |                           |
| 15-20                           | 277 (79.14%)  | 183 (45.75%)   | <0.001                    |
| 21-25                           | 72 (20.58%)   | 178 (44.50%)   |                           |
| 26-30                           | 00 (0.00%)    | 34 (08.50%)    |                           |
| 31-35                           | 01 (0.28%)    | 05 (01.25%)    |                           |
| Diet                            |               |                |                           |
| Vegetarian                      | 96 (27.42%)   | 118 (29.50%)   | 0.59                      |
| Mixed                           | 254 (72.58%)  | 282 (70.50%)   |                           |
| Education                       |               |                |                           |
| High School                     | 139 (39.71%)  | 108 (27.00%)   | <0.001                    |
| High School graduate (12 y)     | 24 (06.86%)   | 49 (12.25%)    |                           |
| College /Graduate               | 43 (12.29%)   | 129 (32.25%)   |                           |
| No School                       | 144 (41.14%)  | 114 (28.50%)   |                           |
| Economic status                 |               |                |                           |
| Poor                            | 198 (56.58%)  | 132 (33.00%)   | <0.001                    |
| Middle                          | 97 (27.71%)   | 161 (40.25%)   |                           |
| Rich                            | 55 (15.71%)   | 107 (26.75%)   |                           |
| Family history of Cancer        |               |                |                           |
| Yes                             | 62 (17.71%)   | 10 (02.50%)    | <0.001                    |
| No                              | 288 (82.29%)  | 390 (97.50%)   |                           |

**Analysis of the Arg188His polymorphism in the XRCC2 gene**

Table 2 displays the distribution of genotypes and frequency of alleles of the G31479A polymorphisms in patients with CC and controls. We did not find any significant difference in genotype or allele frequencies between patients and controls. The frequency of XRCC2 31479GG wild type alleles at codon 188 of exon 3 was 78.86%, 31479GA heterozygote alleles was 19.43% and for 31479AA homzygous alleles was 1.71% in the cases where that of the frequencies for the controls were 79.25, 18.00 and 2.75% respectively (Table 2). Thus, the haplotype analysis according to variant type of G31479A showed a lack of association with CC.

**Analysis of the Thr241Met polymorphism in the XRCC3 gene**

Allele frequencies and distribution of genotypes of XRCC3 codon 241 are shown in Table 2. In frequency distribution of codon 241 of XRCC3 gene at C18067T, genotype frequencies for wild, heterozygote and variant genotypes were 68.00, 26.57 and 5.43% respectively in cases where as the frequencies in controls were 71.00, 24.25 and 4.75% respectively. XRCC3 241 Met/Met, Thr/Met and Met/Met genotypes did not show significant association with development of CC (OR=1.19, 95% CI=0.61-2.30; p= 0.59 for 241 Met/Met) (Table 2).

**Association of age of cancer occurrence, tobacco status and age at 1st pregnancy with cervical cancer risk**

In the studied population, the median age of commencement of CC is 47 years, substantially lower than observed in other reports. To evaluate the association of the polymorphisms with the young age at diagnosis of cervical cancer, we stratified the patients as ≤50 (n=216) or >50 (n=134) years of age and compared with age matched sample of controls which interestingly showed that the XRCC1 cd 280 (OR=4.19; CI=2.87-6.12; p<0.0001) showed significant risk of CC at the age of 25 years.
bellow median. Also, when we studied plausible association of demographic factors and polymorphism in XRCC1, XRCC2, XRCC3 genes, our results indicated non-vegetarian diet and tobacco chewing habits also showed connection with CC development (OR=6.53; CI=4.43-9.61; p<0.0001) for mixed diet and (OR=5.14; CI=3.03-8.70; p<0.0001) for tobacco chewing status (Table 3).

Table 2: The genotype frequencies of XRCC gene polymorphisms in untreated cervical cancer patients and controls.

| Gene    | Genotype          | Cases (n= 350) (%) | Control (n = 400) (%) | Odds' ratio (95% CI) | P value | Adjusted odds ratio (95% CI) | P value |
|---------|-------------------|--------------------|-----------------------|----------------------|---------|-----------------------------|---------|
| XRCC1   | Arg/Arg           | 279 (79.71)        | 316(79.00)            | 1                    | 1       | 1                           | 1       |
|         | Arg/Trp           | 71 (20.29)         | 78(19.50)             | 1.03 (0.72-1.48)     | 0.86    | 0.85 (0.58-1.27)            | 0.44    |
|         | Trp/Trp           | 0 (0.00)           | 6 (1.50)              | 0.08 (0.04-1.55)     | 0.09    | NA                          | NA      |
|         | Arg/Trp+Trp/Trp   | 71 (20.29)         | 84 (21.00)            | 1.06 (0.75-1.50)     | 0.72    | 0.84 (0.54-1.19)            | 0.27    |
| XRCC1   | Arg/Arg           | 137 (39.14)        | 295 (73.75)           | 1                    | 1       | 1                           | 1       |
|         | Arg/His           | 0 (0.00)           | 0 (0.00)              | NA                   | NA      | NA                          | NA      |
|         | His/His           | 213 (60.86)        | 105 (26.25)           | 4.36 (3.20-5.95)     | <0.0001*| 4.27 (3.096-5.882)          | <0.0001 |
|         | Arg/His+His/His   | 213 (60.86)        | 105 (26.25)           | 4.36 (3.20-5.95)     | <0.0001*| 4.27 (3.096-5.882)          | <0.0001 |
| XRCC1   | Arg/Arg           | 137 (39.14)        | 246 (61.50)           | 1                    | 1       | 1                           | 1       |
|         | Arg/Gln           | 183 (52.29)        | 136 (34.00)           | 2.41 (1.78-3.27)     | 0.0001  | 2.38 (1.72-3.31)            | <0.0001 |
|         | Gln/Gln           | 30 (08.57)         | 18 (04.50)            | 2.99 (1.60-5.56)     | 0.0001* | 2.91 (1.49-5.66)            | <0.0001 |
|         | Arg/Gln+ Gln/Gln  | 213 (60.96)        | 154 (38.50)           | 2.48 (1.85-3.33)     | 0.0001* | 2.43 (1.77-3.33)            | <0.0001 |
| XRCC2   | Arg/Arg           | 276 (78.86)        | 317 (79.25)           | 1                    | 1       | 1                           | 1       |
|         | Arg/His           | 68 (19.43)         | 72 (18.00)            | 1.08 (0.75-1.56)     | 0.66    | 0.94 (0.62-1.42)            | 0.77    |
|         | His/His           | 6 (01.71)          | 11 (02.75)            | 0.62 (0.22-1.71)     | 0.36    | 0.57 (0.19-1.72)            | 0.32    |
|         | Arg/His+His/His   | 74 (21.14)         | 83 (20.75)            | 1.02 (0.71-1.45)     | 0.89    | 0.89 (0.60-1.32)            | 0.56    |
| XRCC3   | Thr/Thr           | 238 (68.00)        | 284 (71.00)           | 1                    | 1       | 1                           | 1       |
|         | Thr/Met           | 93 (26.57)         | 97 (24.25)            | 1.14 (0.82-1.56)     | 0.42    | 1.04 (0.72-1.51)            | 0.82    |
|         | Met/Met           | 19 (05.43)         | 19 (04.75)            | 1.19 (0.61-2.30)     | 0.59    | 1.23 (0.61-2.49)            | 0.56    |
|         | Thr/Met+Met/Met   | 112 (32.00)        | 116 (29.00)           | 1.15 (0.84-1.57)     | 0.37    | 1.07 (0.77-1.51)            | 0.67    |

*Indicates significant Odds Ratio (p<0.001), p value determined based on χ²

Table 3: Stratification of age of cancer occurrence, tobacco smoking and distribution of XRCC1, XRCC2 and XRCC3 genotypes in the patients with CC and control group from rural population of Maharashtra.

| Gene    | Genotype          | Demographic Factors | Tobacco Status, Cases/Controls |
|---------|-------------------|---------------------|--------------------------------|
|         |                   | Age, Cases/Controls | Non-Users, N=161/288          |
|         |                   | ≤50, N=216/286      | >50, N=134/114                 |
| XRCC1   | Arg/Arg           | 174/225             | 153/89                         | 126/227 |
|         | Arg/Trp+ Trp/Trp  | 42/61               | 36/23                          | 35/61   |
| OR      | (95% CI)          | 0.89 (0.57-1.38)    | 0.91 (0.50-1.63)               | 1.03 (0.64-1.65) |
| p value |                   | 0.60                | 0.77                           | 0.7     | 0.88                           |
| XRCC1   | Arg/Arg           | 83/207              | 74/86                          | 63/209  |
|         | Arg/His+His/His   | 133/79              | 115/26                         | 98/79   |
| OR      | (95% CI)          | 4.19 (2.87-6.12)    | 5.14 (3.03-8.70)               | 4.11 (2.73-6.19) |
| p value |                   | <0.0001             | <0.0001                        | <0.0001 |
| XRCC1   | Arg/Arg           | 78/190              | 73/68                          | 64/178  |
|         | Arg/Gln+ Gln/Gln  | 138/96              | 116/44                         | 97/110  |
| OR      | (95% CI)          | 3.50 (2.41-5.07)    | 2.45 (1.52-3.96)               | 2.45 (1.65-3.64) |
| p value |                   | <0.0001             | 0.02                           | <0.0001 |
| XRCC2   | Arg/Arg           | 173/234             | 151/85                         | 125/232 |
|         | Arg/His+His/His   | 43/52               | 38/27                          | 36/56   |
| OR      | (95% CI)          | 0.89 (0.57-1.40)    | 0.79 (0.45-1.38)               | 1.19 (0.74-1.91) |
| p value |                   | 0.62                | 0.41                           | 0.46    |
| XRCC3   | Thr/Thr           | 152/212             | 130/86                         | 108/198 |
|         | Thr/Met+Met/Met   | 64/74               | 59/26                          | 53/90   |
| OR      | (95% CI)          | 0.80 (0.55-1.22)    | 1.50 (0.87-2.56)               | 1.07 (0.71-1.63) |
| p value |                   | 0.35                | 0.13                           | 0.71    |
Table 4: Stratification of age at first pregnancy and distribution of XRCC1, XRCC2 and XRCC3 genotypes in the patients with CC and control group from rural population of Maharashtra.

| Gene     | Genotype       | Demographic Factors | Age@ 1\textsuperscript{st} Pregnancy, Cases/Controls |
|----------|----------------|---------------------|-----------------------------------------------------|
|          |                |                     | 15-20                                               |
|          |                |                     | N=277/183                                            |
|          |                |                     | 21-25                                               |
|          |                |                     | N=72/178                                             |
|          |                |                     | 26-30                                               |
|          |                |                     | N=0/34                                               |
|          |                |                     | 31-35                                               |
|          |                |                     | N=1/5                                                |
| XRCC1    | Arg/Arg        |                     | 220/138                                             |
| Arg194Trp| Arg/Trp+Trp/Trp|                     | 57/45                                               |
| cd194 exon6| OR (95% CI)   |                     | 0.79 (0.50-1.23)                                    |
| CD26304T | p value        |                     | 0.96                                               |
|          |                |                     | 0/31                                                |
|          |                |                     | 1/4                                                 |
| XRCC3    | Arg/Arg        |                     | 110/126                                             |
| Arg280His| Arg/His+His/His|                     | 167/57                                              |
| cd280 exon9| OR (95% CI)   |                     | 3.35 (2.26-4.98)                                    |
| G27466A  | p value        |                     | <0.0001                                             |
|          |                |                     | 0/19                                                |
|          |                |                     | 0/5                                                 |
| XRCC1    | Arg/Arg        |                     | 113/96                                              |
| Arg399Gln| Arg/Gln+Gln/Gln|                     | 164/87                                              |
| cd399 exon10| OR (95% CI) |                     | 1.60 (1.09-2.33)                                    |
| G28152A  | p value        |                     | 0.01                                               |
|          |                |                     | <0.0001                                             |
|          |                |                     | 0/14                                                |
|          |                |                     | 0/3                                                 |
| XRCC2    | Arg/Arg        |                     | 219/136                                             |
| Arg188His| Arg/His+His/His|                     | 58/47                                               |
| cd188 exon3| OR (95% CI)   |                     | 0.76 (0.49-1.19)                                    |
|          | p value        |                     | 0.23                                               |
|          |                |                     | 0.27                                                |
|          |                |                     | 0.52                                                |
|          |                |                     | 0.55                                                |
| XRCC3    | Thr/Thr        |                     | 190/121                                             |
| Thr241Met| Thr/Met+Met/Met|                     | 87/62                                               |
| cd241 exon7| OR (95% CI)   |                     | 0.89 (0.60-1.32)                                    |
| C18067T  | p value        |                     | 0.57                                               |
|          |                |                     | 0.09                                                |
|          |                |                     | 0.67                                                |
|          |                |                     | 1.00                                                |

*: Indicates significant Odds Ratio (p<0.001); p value determined based on χ²

Also, the association of CC with age at first pregnancy was considered in this study which showed that early age of first pregnancy i.e.15-20 yrs, significantly associated with increased CC risk (OR=3.25; CI=2.26-4.98; p<0.0001) (Table 4).

DISCUSSION

In this hospital based case-control study, we examined the genotypic frequency of polymorphisms of the (i) XRCC1 gene at cd 194, cd 280, cd 399 (ii) XRCC2 gene at cd188 (iii) XRCC3 gene at cd 241 of exon 7 to study the associated risk of cervical carcinoma among the rural population of south-western Maharashtra. The results interpreted that the OR associated with His 280 genotype (OR = 4.36; 95% CI = 3.20-5.95) and Gln399 genotype (OR= 2.99; 95% CI= 1.60-5.56) of XRCC1 were significantly increased in relation to the relative risk of cervical cancer in the study. Over the past few years, a number of epidemiological studies have been conducted to demonstrate the association of XRCC1, XRCC2, XRCC3 polymorphism with susceptibility to gastric, lung, breast cancer, and other types of cancers.\textsuperscript{24,25} However, little published information is available regarding the association between polymorphism of XRCC1, XRCC2 and XRCC3 gene and susceptibility to cervical carcinoma.\textsuperscript{26} Also, few studies from Northern and Southern India have reported the genetic polymorphisms in the DNA repair genes with respect to a variety of cancer risks including prostate, breast, oral and esophageal cancers, but only couple of studies available to reveal the association of polymorphisms in XRCC1, XRCC2 and XRCC3 genes with CC development and the results were with incompatible conclusions.\textsuperscript{27,28} Some recent studies discovered positive association of Arg194Trp variant of XRCC1 with CC development risk while other demonstrated a strong association of the Arg399Gln polymorphism with an increased risk of CC, but other failed to find the significant result.\textsuperscript{29,30} No apparent association observed between Arg280His polymorphisms of XRCC1 and cervical cancer risk in any of the published study.\textsuperscript{29} On the other hand, in a more recent report showed a weak association of XRCC1 gene in development of CC, however two studies by Zeng et al and Cai et al reported no evidence of association of XRCC genes with CC development.\textsuperscript{31,32} Thus, there is a debate between association or no association between XRCC1 gene and risk of development of CC. Also, reports on XRCC2 Arg188His polymorphisms stated that XRCC2 variants were found not to be associated with CC risk.\textsuperscript{30} Similarly, studies have been conducted to prove that polymorphisms of XRCC3 gene may be involved in reducing DNA repair capacity but the direct evidence in terms of the associations with CC susceptibility have been proved contradictory.\textsuperscript{19}

However, no information is available on the association of genetic polymorphisms of DNA repair genes including...
2. Institutional Ethical Committee: Summary Report on HPV and Cervical Cancer Statistics in South Africa.(Onlin). 2010.
4. Sharma N, Sharma V, Singh PR, Kushwaha RS, Nautiyal SC, Sailwal S, et al. Age wise distribution of high risk Human Papillomavirus in Northern Indian women. Biomed Res India. 2012;23:547-50.
5. Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N, et al. Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathology Research International. 2011.
6. Thacker J, Zdzienicka MZ. The mammalian XRCC genes: their roles in DNA repair and genetic stability. DNA Repair (Amst). 2003;2:655-72.
7. Vidal AE, Boiteux S, Hickson ID, Radicella JP. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J. 2001;20:6530-9.
8. Mathonnet G, Labuda D, Meloche C, Wambach T, Krajnovic M, Sinnett D. Variable continental distribution of polymorphisms in the coding regions of DNA-repair genes. J Human Genetics. 2003;48(12):659.
9. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiology and Prevention Biomarkers. 2003 Aug 1;12(8):689-98.
10. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513-30.
11. Au WW, Navasumrit P, Ruchirawat M. Use of biomarkers to characterize functions of polymorphic DNA repair gene mutations. Int J Hyg Environ Health. 2004;207:301-13.
12. Wei B, Zhou Y, Xu Z, Ruan J, Zhu M, Jin K, et al. XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis. Prostate cancer and prostatic diseases. 2011;14(3):225-31.
13. Dai L, Duan F, Wang P, Song C, Wang K. XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case-control studies. Mol Biol Rep. 2012;39:9535-47.
14. Datkhile KD, Vhaval RD, Patil MN, Khamkar TS, Durgavale PP, Guddar U. Role of genetic polymorphisms in DNA repair genes (XRCC1, XRCC2, XRCC3, XRCC4, XRCC5, XRCC6, XRCC7) in head and neck cancer susceptibility in rural Indian population: A hospital based case-control study from south-western Maharashtra. Int J Curr Res. 2016;8:25482-92.
15. Bin K, Zhi-Dong L, Li C, Ruo-Wu S, Li-Ying J, Zhao-Chuan Y. Lack of an association between XRCC2 R188H polymorphisms and breast cancer: an update meta-analysis involving 35,422 subjects. Int J Clin Exp Med. 2015;8:15808-14.
16. Huang G, Cai S, Wang W, Zhang Q and Liu A. Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: A meta-
17. Qureshi Z, Mahjabeen I, Baig R, Kayani M. Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan. Asian Pac J Cancer Prev. 2014;15:10225-9.

18. Wang X, Yang Z. The relationship of XRCC1 gene polymorphism and the risk of cervical cancer. Modern Medicine and Health. 2010;26:2137-8.

19. Settheetham-Ishida W, Yuenyao P, Natphopsuk S, Settheetham D, Ishida T. Genetic Risk of DNA Repair Gene Polymorphisms (XRCC1 and XRCC3) for High Risk Human Papillomavirus Negative Cervical Cancer in Northeast Thailand. Asian Pac J Cancer Prev. 2011;12:963-9.

20. Perez LO, Crivaro A, Barbisan G Poleri L, Golijaw CD. XRCC2 R188H (rs3218536), XRCC3 T241M (rs861539) and R243H (rs77381814) single nucleotide polymorphisms in cervical cancer risk. Pathol. Oncol. Res. 2013;19(3):553-558.

21. Zhang L, Ruan Z, Hong Q, Gong X, Hu Z, Huang Y, Xu A. Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: a case-control study. Oncol Lett. 2012;3:351-62.

22. Bajpai D, Banerjee A, Pathak S, Jain S, Singh N. Prognostic importance of DNA repair gene polymorphisms in cervical cancer patients from India. Sex Transm Infect. 2015;91:A167.

23. Konathala G, Mandarapu R and Godi S. Data on polymorphism of XRCC1 and cervical cancer risk from South India. Data in Brief. 2017;10:11-3.

24. Park JY, Lee SY, Jeon HS, Bae NC, Chae SC, Joo S, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiology and Prevention Biomarkers. 2002;11(1):23-7.

25. Kim SU, Park SK, Yoo KY, Yoon KS, Choi JY, Seo JS, et al. XRCC1 genetic polymorphism and breast cancer risk. Pharmacogenetics and Genomics. 2002;12(4):335-8.

26. Liu DY, Liang HC, Xiao XM. Association between the XRCC1 Arg399Gln polymorphism and risk of cervical carcinoma: a meta-analysis. Genet Mol Res. 2015;14:9821-8.

27. Pachouri SS, Sobti RC, Kaur P and Singh J. Contrasting impact of DNA repair gene XRCC1 polymorphisms Arg399Gln and Arg194Trp on the risk of lung cancer in North Indian population. DNA Cell Biol. 2007;26:186-91.

28. Vettriselvi V, Vijayalakshmi K, Solomon FD, Paul VP, XRCC1 and XPD Gene Polymorphisms in a South Indian Population. Asian Pacific J Cancer Prev. 2007;8:283-6.

29. Mei J, Duan HX, Wang LL, Yang S, Lu QJ, Shi TY, Zhao Y. XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis. Tumour Biol. 2014;35:1221-31.

30. Shuai HL, Luo X, Yan RL, Li J, Chen DL. XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:6423-7.

31. Cai Y, Wang QM, Feng JH, Chen L, Zhang ST, Huang Y. Association between XRCC1 Arg399Gln, Arg280His, Arg194Trp polymorphisms and cervical cancer risk: a pooled analysis based on Chinese individuals. Int J Clin Exp Med. 2017;10(9):13003-8.

32. Zeng X, Zhang Y, Yue T, Zhang T, Wang J, Xue Y, An R. Association between XRCC1 polymorphisms and the risk of cervical cancer: a meta-analysis based on 4895 subjects. Oncotarget. 2017;8(2):2249-60.

Cite this article as: Datkhile KD, Patil MN, Durgawale PP, Joshi SA, Korabu KS, Kakade SV. Assessment of role of genetic polymorphisms in XRCC1, XRCC2 and XRCC3 in cervical cancer susceptibility from a rural population: a hospital based case-control study from Maharashtra, India. Int J Res Med Sci 2018;6:3132-9.